Trials / Recruiting
RecruitingNCT05312879
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Adult and Pediatric Subjects With APOL1-mediated Proteinuric Kidney Disease
- Status
- Recruiting
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 466 (estimated)
- Sponsor
- Vertex Pharmaceuticals Incorporated · Industry
- Sex
- All
- Age
- 10 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VX-147 | Tablets for oral administration. |
| DRUG | Placebo | Tablets for oral administration. |
Timeline
- Start date
- 2022-03-30
- Primary completion
- 2028-06-02
- Completion
- 2030-05-07
- First posted
- 2022-04-06
- Last updated
- 2026-04-17
Locations
318 sites across 13 countries: United States, Belgium, Brazil, Canada, Colombia, France, Ghana, Netherlands, Nigeria, Portugal, Puerto Rico, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05312879. Inclusion in this directory is not an endorsement.